Aumolertinib mesylate is under clinical development by Jiangsu Hansoh Pharmaceutical Group and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase I drugs for Lung Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Aumolertinib mesylate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aumolertinib mesylate overview
Aumolertinib mesylate (Ameile) is an anti neoplastic agent. It is formulated as tablets for oral route of administration. Ameile is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after other EGFR tyrosine kinase inhibitor (TKI) therapy.
HS-10296 is under development for the first line treatment of locally advanced or metastatic non-small cell lung cancer and pulmonary adenosquamous carcinoma. The drug candidate is a third-generation EGFR inhibitor. It is administered through oral route as a once-daily formulation. It acts by targeting the epidermal growth factor receptor (EGFR).
Jiangsu Hansoh Pharmaceutical Group overview
Jiangsu Hansoh Pharmaceutical Group (Hansoh Pharma), a subsidiary of Hansoh Pharmaceutical Group Co Ltd, is a pharmaceutical company. The company carries out the research and development of drugs in the therapeutic areas of oncology, anti-infectives, central nervous system (CNS) diseases, metabolic diseases and autoimmune diseases. Hansoh Pharma provides marketing services, lean manufacturing services, and quality management services. The company markets its products under the brands Amelie, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, and Hengsen, among others. Hansoh Pharma is headquartered in Lianyungang, Jiangsu, China.
For a complete picture of Aumolertinib mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
